UNIVERSITY^{OF} BIRMINGHAM University of Birmingham Research at Birmingham

Sub-5-minute detection of SARS-CoV-2 RNA using a Reverse Transcriptase-Free Exponential Amplification Reaction, RTF-EXPAR

Carter, Jake G.; Iturbe, Lorea Orueta; Duprey, Jean-Louis H. A.; Carter, Ian R.; Southern, Craig D.; Rana, Marium; Bosworth, Andrew; Beggs, Andrew D.; Hicks, Matthew R.; Tucker, James H. R.; Dafforn, Timothy R.

DOI: 10.1101/2020.12.31.20248236

License: Creative Commons: Attribution (CC BY)

Document Version Early version, also known as pre-print

Citation for published version (Harvard):

Carter, JG, Iturbe, LO, Duprey, J-LHA, Carter, IR, Southern, CD, Rana, M, Bosworth, A, Beggs, AD, Hicks, MR, Tucker, JHR & Dafforn, TR 2021, 'Sub-5-minute detection of SARS-CoV-2 RNA using a Reverse Transcriptase-Free Exponential Amplification Reaction, RTF-EXPAR', *medRxiv*, vol. 2021, pp. 1-7. https://doi.org/10.1101/2020.12.31.20248236

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.31.20248236; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Sub-5-minute Detection of SARS-CoV-2 RNA using a Reverse Transcriptase-1 **Free Exponential Amplification Reaction, RTF-EXPAR** 2

3

7 8

9

10

Jake G. Carter,^{1,2} Lorea Orueta Iturbe,³ Jean-Louis H. A. Duprey,³ Ian R. Carter,⁵ Craig D. Southern,⁵ 4 5 Marium Rana,¹ Andrew Bosworth,⁴ Andrew D. Beggs,⁴ Matthew R. Hicks,³ James H. R. Tucker,^{1*} 6 and Timothy R. Dafforn^{2*}

- 1. School of Chemistry, University of Birmingham, Edgbaston, Birmingham, UK, B15 2TT.
- 2. School of Biosciences, University of Birmingham, Edgbaston, Birmingham, UK, B15 2TT.
- 3. Linear Diagnostics Ltd, 97 Vincent Drive, Edgbaston, Birmingham, UK, B15 2SO.
- 4. Institute of Cancer and Genomics, University of Birmingham, Edgbaston, Birmingham, UK, 11 12 B15 2TT.
- 13 14
- 5. C2JF Solutions LLP, 35 Meridian Business Village, Speke, Liverpool, L24 9LG.

15 We report a rapid isothermal method for detecting SARS-CoV-2, the virus responsible for 16 COVID-19. The procedure uses a novel reverse transcriptase-free (RTF) approach for 17 converting RNA into DNA, which triggers a rapid amplification using the Exponential 18 Amplification Reaction (EXPAR). Deploying the RNA-to-DNA conversion and amplification 19 stages of the RTF-EXPAR assay in a single step results in the detection of a sample of patient 20 SARS-CoV-2 RNA in under 5 minutes.

- 21 22 In order to reduce the rate of spread of COVID-19, an accurate and efficient virus testing strategy is 23 imperative. A key part of this strategy is continuous assay development, with the aim of reducing 24 detection times and increasing sample throughput. The research community and diagnostics industry 25 has responded rapidly to this unprecedented crisis in developing a range of detection platforms.¹⁻⁴ 26 The most sensitive assays detect viral RNA, with the current gold standard being reverse transcriptase 27 polymerase chain reaction (RT-PCR), a two-step assay that takes more than 60 minutes per sample. 28 First, reverse transcriptase converts viral RNA to complementary DNA (cDNA), a process that can 29 take up to 30 minutes.⁵ Then a quantitative PCR (gPCR) amplifies the cDNA, which is detected using a fluorescent dye, a process that takes up to an hour.⁶ To reduce assay times, a plethora of new 30 31 approaches to SARS-CoV-2 detection have appeared in the literature over the past year. As far as 32 Nucleic Acid Amplification Tests (NAATs) are concerned, which are more sensitive than current 30minute lateral flow antigen (immunoassav) tests.⁷ focus has turned towards isothermal DNA 33 amplification approaches, which increase amplification speeds and hence reduce assay times. The 34 35 most common isothermal amplification system is Loop mediated isothermal AMPlification (LAMP).⁸ 36 LAMP assays have been developed for SARS-CoV-2 but take, on average, 20 minutes for a result, with further decreases in LAMP assay time proving challenging.^{4,9,10} Herein, we demonstrate an 37 38 alternative isothermal approach based on the Exponential Amplification Reaction (EXPAR),¹¹ a 39 simpler and faster amplification method than LAMP. By combining EXPAR with a novel reverse 40 transcriptase-free (RTF) step, this new assay, RTF-EXPAR, can accurately identify viral RNA 41 derived from COVID-19 patient samples in less than 5 minutes.
- 42

43 The key to the speed of EXPAR is twofold; firstly, the amplification occurs at a single temperature, 44 thus avoiding lengthy heating and cooling steps, and secondly the amplicon is relatively small 45 (typically 15-20 bases long), compared to both PCR and LAMP. These two factors result in EXPAR, 46 once triggered, producing up to 10⁸ strands of DNA product in a matter of minutes.^{11,12} A singlestranded DNA fragment (the trigger) starts the EXPAR reaction by binding a DNA template. Large 47 48 quantities of short double stranded DNA sequences are then generated in an isothermal cycle 49 involving a DNA polymerase to extend the sequence and a nicking endonuclease to cut it, while 50 leaving the template intact (Scheme 1a). As with the RT-PCR COVID-19 assay, duplex formation is 51 monitored spectroscopically using a fluorescent intercalating dye, e.g. SYBR Green.

52

53 A crucial element to developing a successful EXPAR assay is the identification of optimal nucleotide 54 sequences in the target genome. Qian *et al* previously found that the type of trigger sequence used in EXPAR plays a vital role in determining its efficiency.^{13,14} Using their approach, we designed a 17-55 56 mer DNA trigger for EXPAR (Trigger X, Scheme 1a and Table 1) containing a sequence 57 complementary to one within the conserved gene Orflab in the SARS-CoV-2 genome 58 (https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3?report=fasta). We first analysed the speed and 59 sensitivity of EXPAR using Trigger X in the presence of Template X'-X' (Supplementary Figure 60 1). Rapid rises in SYBR Green fluorescence were observed, with amplification times revealing an expected dependence on trigger concentration (e.g. time to 10-sigma: 3.17 ± 0.14 minutes at 10 nM, 61 62 8.67 ± 1.08 minutes at 10 pM). These results demonstrate that EXPAR is a faster amplification 63 method than LAMP. Next, we analysed the specificity of the reaction by investigating three other 64 triggers (Triggers A, B and C), each at a concentration of 10 nM, that were non-complementary to **Template X'-X'** (Supplementary Figure 2). Each of these three triggers produced no signal within 65 66 10 minutes under the same conditions, confirming the specificity of the EXPAR reaction, with only 67 the trigger sequence fully complementary to the template (**Trigger X**) resulting in rapid amplification.

68

69 In the standard RT-PCR COVID-19 assay, reverse transcriptase converts the RNA of SARS-CoV-2 70 into cDNA prior to amplification (vide supra). The speed of this initial polymerisation reaction is a 71 significant limitation for this or potentially any other RNA detection method that proceeds via cDNA 72 amplification, including LAMP or EXPAR. We hypothesised that a faster method could be achieved 73 by generating a short DNA trigger sequence directly from the RNA genomic strand, without the need 74 for a lengthy reverse transcriptase step. Murray et al had previously demonstrated that the restriction 75 enzyme BstNI could act as a nicking enzyme by selectively cleaving DNA within RNA:DNA 76 heteroduplexes.¹⁵ We considered that this enzyme could be used to generate the desired DNA 77 fragment for triggering the EXPAR reaction. To achieve this, we designed a 30-mer oligonucleotide 78 (called **Binder DNA**, Table 1) possessing a 5-base recognition site for *Bst*NI, as well as two partially 79 overlapping sequence stretches complementary to part of Orflab in the SARS-CoV-2 RNA genome 80 and the EXPAR DNA template (Template X'-X'). Site-selective cleavage of Binder DNA using 81 BstNI would only occur in the presence of the RNA target from SARS-CoV-2, generating a shorter 82 strand of DNA, Trigger X (Scheme 1b). This shorter strand would now release from the heteroduplex 83 and bind preferably to the DNA template, as it can still form a fully-complementary 17-mer duplex 84 with the latter. Binding to the template would trigger EXPAR, with the newly released RNA strand 85 able to bind more **Binder DNA** to generate more **Trigger X**. 86

87 Applying this novel EXPAR approach in a two-stage process, we first undertook an enzymatic 88 digestion at 50 °C for five minutes of **Binder DNA** (1 µM) in the presence of a sample of patient 89 SARS-CoV-2 RNA (72.7 copies/ μ L)¹⁶ obtained from PHE, before adding this solution to the EXPAR reagent mix for the amplification step. This stage, performed in triplicate, gave an amplification time 90 91 of 3.17 ± 0.24 minutes, whereas no amplification was observed for the negative sample within 10 92 minutes (Fig. 1 and Supplementary Figure 3). To increase the speed of the RTF-EXPAR assay further, 93 we next investigated a "one-pot" approach by introducing BstNI and Binder DNA to the EXPAR 94 reagents at the same time, before incubating and amplifying simultaneously at 50 °C. These assay 95 conditions gave an amplification time of only 4.00 ± 0.72 minutes for the positive sample, halving 96 the total assay time compared to the "two-pot" method (Fig. 1 and Supplementary Figure 4). Once 97 again, no signal change for the negative sample was observed within 10 minutes. As expected, this 98 was also the case for control experiments on the positive RNA sample in the absence of either Binder 99 **DNA** or **Template X'-X'** (see Supplementary Figures 5 and 6 respectively), and a sample of RNA 100 isolated from the CFPAC-1 human ductal pancreatic adenocarcinoma cell line (see Supplementary 101 Figure 7).

102

103 In conclusion, through the use of a new reverse transcriptase-free isothermal amplification method, 104 RTF-EXPAR, involving a DNA-selective restriction endonuclease, we have demonstrated the

105 successful detection of SARS-CoV-2 RNA in a total assay time of less than 5 minutes. This time is 106 not only much faster than RT-PCR (assay time of at least 60 minutes) but also outperforms LAMP 107 and 30-minute lateral flow antigen tests in current deployment. RTF-EXPAR would be completely 108 compatible (i.e. deployment ready) for use on equipment currently used for RT-PCR COVID-19 109 assays. Furthermore, the simplicity and speed of the assay enables this method to be modified to 110 detect a range of infectious diseases caused by RNA-based pathogens (e.g. Ebola, RSV). 111 112 (a) Exponential Amplification Reaction (EXPAR)



150 Scheme 1. (a) Reaction Scheme for EXPAR: Trigger X anneals to Template X'-X' and is extended by a 151 DNA polymerase (Bst 2.0 polymerase); the top strand of the newly formed duplex DNA is then cut by a nicking 152 enzyme (Nt.BstNBI); the released DNA (which is displaced by DNA polymerase in a subsequent extension 153 reaction) is identical to Trigger X and is therefore able to prime another Template X'-X'. (b) Reaction Scheme 154 for Reverse Transcriptase-Free EXPAR (RTF-EXPAR): Binder DNA anneals to viral RNA; the DNA strand 155 of the DNA:RNA heteroduplex is cut by the restriction endonuclease BstNI, which acts as a nicking enzyme 156 by cutting the DNA strand only, the released DNA strand is **Trigger X**, which is then amplified by EXPAR.







Figure 1. RTF-EXPAR assay data for SARS-CoV-2 RNA detection (72.7 copies/ μ L, n = 3), showing: (a) the mean time for the amplification reaction only and (b) the mean total assay time from RNA sample to signal. Each run time was calculated to be the point at which the fluorescence signal was greater than 10 standard deviations from the baseline signal (10-sigma time). Error bars in datasets are the standard deviations of the 10-sigma time. Signals observed for negative samples at >10 min are attributed to amplification arising from non-specific interactions.

Table 1. Oligonucleotides used in study.

Name	Sequence $(5' - 3')$
Trigger X	AGG GTA AAC CAA ATA CC
Trigger A	AGG GTT AAA CCA CCG CC
Trigger B	AGG GTC CTT AAC TTG CC
Trigger C	CCG GGA TTG GTT GAT
Template X ⁻ X ⁻	GGT ATT TGG TTT ACC CTG TGA GAC TCT GGT ATT TGG TTT ACC CT
Binder DNA	agg g ta aac caa ata <mark>CCT gg</mark> t gta tac gtt

Key: Magenta – Non-binding fragment, Blue – BstNI recognition site (complementary to required 5'-CCAGG-3' sequence in RNA target); Bold – Trigger X sequence in Binder DNA sequence

175 Acknowledgments

176 We would like to thank Dr A. Lovering for providing experimental equipment. We would also like 177 to thank Public Health England for supplying the isolated patient RNA from SARS-CoV-2. This 178 research was funded by the Midlands Integrative Bioscience Training Partnership funded by the 179 Biotechnology and Bioscience Research Council (BB/R506175/1). There are no other competing 180 interests.

182 **Author Contributions**

183 T.R.D, M.R.H and J.H.R.T supervised the project; J.G.C, J-L.H.A.D, L.O.I, T.R.D, M.R.H and

- J.H.R.T designed the assay; A.D.B suggested the target gene and A.B. supplied the genomic material; 184
- 185 I.R.C and C.D.S designed the analysis software; J.G.C undertook the research; J.G.C, T.R.D and 186 J.H.R.T. wrote the manuscript.
 - 187

181

188 **Experimental Section**

189 **Materials:** Milli-O water purified with a Millipore Elix-Gradient A10 system (resistivity > 18 $\mu\Omega$.cm, TOC \leq 5ppb, Millipore, France) was used in all the experiments. Nt.*Bst*NBI, *Bst*NI and *Bst* 190 191 2.0 Polymerase were obtained from New England Biolabs (Hitchin, UK) as was the buffer, 10x 192 Isothermal amplification buffer (200 mM Tris-HCl, 100 mM (NH₄)₂SO₄, 500 mM KCl, 20 mM 193 MgSO₄, 1% Tween 20, pH 8.8) which was used in all the experiments. Superscript IV Reverse Transcriptase was obtained from ThermoFisher (Paisley, UK), DMSO (> = 99%) was obtained from 194 195 Fisher Scientific (Loughborough, UK) and dsGreen 100x (an analogue of SYBR Green I), was 196 obtained from Lumiprobe (Hannover, De). Bovine Serum Albumin (BSA, diluted to 4 mg/mL in 197 water) and Single-Stranded Binding Protein (SSB, solution of 0.5 mgs in 20 mM Tris-HCl, pH 8.0, 198 0.5 M NaCl, 0.1 mM EDTA, 0.1 mM DTT, 50% Glycerol) was obtained from Sigma-Aldrich (Dorset, 199 UK). All the nucleotide triphosphates and oligonucleotide sequences (desalted) were obtained from 200 Sigma-Aldrich (Dorset, UK).

201

202 **PHE samples:** All clinical specimens were handled in a Containment Level 2 laboratory. To prepare 203 each sample, Viral Transfer Medium (VTM, 300 µL, Medical Wire ViroCult) from a nose and throat 204 swab was added to Buffer AL (Oiagen) in a 1:1 ratio and heated to 60 °C for 30 minutes in a calibrated 205 heat block. Samples were then extracted on the MagNAPure96 (Roche) automated extraction system 206 and then run on the Abbott M2000 RT-qPCR Test for SARS-CoV-2 RNA Detection. For EXPAR 207 assay development, positive and negative samples from the SARS-CoV-2 RNA assays were 208 separately combined in MagNA Pure elution buffer (giving 29.080 RNA copies/µL for the combined 209 positive sample). Upon receipt from PHE, each sample was diluted 400-fold with water, aliquoted 210 into 50 µL vials and stored at -80 °C. Prior to use, each sample was submerged in ice and allowed to 211 slowly melt; once melted the sample was used immediately before being cooled again for storage at 212 -80 °C.

213

214 Data Analysis and classification: To analyse the EXPAR real-time fluorescence amplification 215 curves and data, a program in C# was developed. The program analyses the first 10 data points and 216 calculates the mean value and standard deviation as a base line. Following generation of these two 217 values, each subsequent data point is analysed to determine if its value minus the average value is greater than 10 standard deviations away from the mean. The cycle which meets this criterion is 218 219 converted into a time and used as the minimum amplification time. Under the concentrations and 220 conditions used in the RTF-EXPAR assay protocol, should the amplification time be less than 10 221 minutes, the output indicates the presence of SARS-CoV-2 RNA (true positive). For amplification 222 times greater than 10 minutes, the output indicates a complete test and the absence of SARS-CoV-2 223 RNA (false positive).

- 224 **RTF-EXPAR Assay Protocol:** The protocol first involves the preparation of three solutions, Part A, 225 Part B and Part C, followed by an addition step and then finally an amplification step.
- 226
- 227 Part A:
- 228 1.50 µL of water, 2.50 µL of 10x Isothermal amplification buffer, 3.75 µL of BSA solution,
- 229 1.50 μ L of Bst 2.0 DNA polymerase (1.6 U/ μ L), 0.75 μ L of Nt.BstNBI (10 U/ μ L). 230
- 231 Part B:
- 232 6.30 μL of water, 5.00 μL of 10x Isothermal amplification buffer, 0.75 μL of Template X'-
- 233 X' (1 µM), 2.40 µL of MgSO₄ (100 mM), 1.50 µL dNTP (10 nM), 0.75 µL of dsGreen (1:5 234 dilution in DMSO from 100x to 20x), 0.30 µL of SSB solution.
- 235 236 Part C:
- 237 (1) Sensitivity test (no RNA target): 3 µL of one trigger at Trigger X (100 nM, 10 nM, 1 nM, 100 238 pM, 10 pM, 1 pM and a blank)
- 239 OR
- 240 (2) Specificity test (no RNA target): 3 µL of one trigger at 100 nM (Trigger X or Trigger A or 241 **Trigger B** or **Trigger C**)
- OR 242

243 (3) Reverse Transcriptase-Free EXPAR assay (two-pot RTF-EXPAR): 10 µL of RNA:DNA

- 244 heteroduplex digestion mixture, prepared as follows: 25 µL of water, 5 µL of 10x Isothermal
- 245 amplification buffer, 5 μ L BstNI (10 U/ μ L), 10 μ L of Binder DNA (1 μ M) and 5 μ L of viral sample. 246 The mixture is then incubated at 50 °C for 5 minutes.
- OR 247
- 248 (4) Reverse Transcriptase-Free EXPAR assay (one-pot RTF-EXPAR): reagents are mixed together 249 in the following order: 1 μ L BstNI (10 U/ μ L), 2 μ L of **Binder DNA** (1 μ M) and 3 μ L of viral sample.
- 250 251 Addition step: Part B (17 µL) is added to a PCR tube, and to this is added Part C, followed by 252 Part A (10 μ L). The tube is then sealed, with the contents then subjected to amplification.
 - 253

254 Amplification step: Isothermal incubation and fluorescence signal measurements are performed using 255 an Agilent Mx3005P Real-Time PCR system (Didcot, UK) set to a constant temperature of 50 °C. 256 The fluorescence is measured every 10 seconds over an incubation time of 30 minutes.

- 257
- 258 259 References
- 260 1. Guglielmi, G. The explosion of new coronavirus tests that could help to end the pandemic. 261 Nature 583, 506-509 (2020).
- 262 2. Venter, M. & Richter, K. Towards effective diagnostic assays for COVID-19: a review. J. Clin. 263 Pathol. 73, 370–377 (2020).
- 264 3. Sheridan, C. Coronavirus and the race to distribute reliable diagnostics. *Nature Biotechnology* 265 38, 382–384 (2020).
- 266 4. Carter, L. J. et al. Assay techniques and test development for COVID-19 Diagnosis. ACS Cent. 267 Sci. 6, 591–605 (2020).
- 268 5. Overbergh, L. et al. The use of real-time reverse transcriptase PCR for the quantification of 269 cytokine gene expression. J. Biomol. Tech. 14, 33-43 (2003).
- 270 Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. 6. 271 Eurosurveillance 25, (2020).

- Mahase, E. Covid-19: Innova lateral flow test is not fit for "test and release" strategy, say
 experts. *BMJ*, **371**, m4469 (2020).
- 8. Notomi, T. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Research* 28, 63e–
 663 (2000).
- 276 9. Rabe, B. A. and Cepko, C. SARS-CoV-2 detection using isothermal amplification and a rapid,
 277 inexpensive protocol for sample inactivation and purification. *Proc. Natl. Acad. Sci. USA* 117,
 278 24450–24458 (2020).
- 279 10. Ganguli, A. *et al.* Rapid isothermal amplification and portable detection system for SARS-CoV280 2. *Proc. Natl. Acad. Sci. USA* 117, 22727–22735 (2020).
- 11. Van Ness, J.; Van Ness, L. K. and Galas, D. J. Isothermal reactions for the amplification of oligonucleotides. *Proc. Nat. Acad. Sci. USA* 100, 4504–4509 (2003).
- Reid, M. S.; Le, X. C. and Zhang, H. Exponential Isothermal Amplification of Nucleic Acids
 and Assays for Proteins, Cells, Small Molecules, and Enzyme Activities: An EXPAR Example. *Angew. Chem. Int. Ed.* 57, 11856–11866 (2018).
- 286 13. Qian, J. *et al.* Sequence dependence of isothermal DNA amplification via EXPAR. *Nucleic* 287 *Acids Research* 40, e87–e87 (2012).
- 14. Reid, M. S.; Paliwoda, R. E.; Zhang, H. and Le, X. C. Reduction of Background Generated
 from Template-Template Hybridizations in the Exponential Amplification Reaction. *Anal. Chem.* 90, 11033–11039 (2018).
- 15. Murray, I. A.; Stickel, S. K. and Roberts, R. J. Sequence-specific cleavage of RNA by Type II
 restriction enzymes. *Nucleic Acids Research* 38, 8257–8268 (2010).
- 16. The average viral load in respiratory samples has been reported to be 10^{5.85} copies/mL, which
 equates to ca. 700 copies/μL; see: Kleiboeker, S. *et al.* SARS-CoV-2 viral load assessment in
 respiratory samples. J. Clin. Virol. 129, 104439 (2020).
- 296